BMO Capital upgraded Genmab to Outperform from Market Perform with a price target of $48, up from $46. Post the fiscal 2023 earnings, the analyst is “incrementally more confident” in Genmab’s ability to diversify its business longer-term, which currently relies heavily on Darzalex revenues from Johnson & Johnso (JNJ). Excluding the pipeline, the firm values Genmab at $43, “which still represents significant upside to shares.” BMO says the company has pipeline optionality with two shots on goal in acasunlimab and GEN3014 with updates for both programs this year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GMAB:
- Genmab price target lowered to DKK 2,400 from DKK 2,500 at RBC Capital
- Genmab price target lowered to $50 from $54 at Truist
- Transactions in connection with share buy-back program
- Notice to Convene the Annual General Meeting of Genmab A/S
- Genmab Files Annual Report with the U.S. Securities and Exchange Commission
